Skip to main content
Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Pharmaceuticals: Generic
Sector Health Technology
Employees 248
CEO Ms. Zhi Lin Li
Address No.17, Jinpan Road 2nd Floor, Haikou, HA 570216
Phone 86.898.6681.173
Website www.chinapharmaholdings.com

China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm’s product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Others, Comprehensive Healthcare and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
China Pharma Holdings, Inc. -26.05% 20.06%
BellRing Brands, Inc. -23.22% 17.36%
ImmunoGen, Inc. -16.49% -9.43%
Heron Therapeutics, Inc. -18.03% -48.10%
Singular Genomics Systems, Inc. -23.64% n/a

Statement Summary

as of 1:10 ET PM 11/26/2021
Total Assets (MRQ) 18.2 M
Total Liabilities (MRQ) 11.3 M
Shareholders’ Equity (MRQ) 6.9 M
Total Revenue (Annual) 2.0 M
Net Income (Annual) -826.7 K

Earnings And Estimates

as of 1:10 ET PM 11/26/2021

Current Qtr EPS Estimate n/a
Current FY EPS Estimate n/a
Long Term EPS Growth Estimate 10.00
Next Expected Earnings Date //

CPHI vs S&P 500

as of 11/26/2021
Relative To
S&P 500
CPHI
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 1:10 ET PM 11/26/2021
Fiscal Quarter Estimate Actual Surprise
09/2011 0.12 0.08 -33.33%
06/2011 0.12 0.12 0.00%
03/2011 0.12 0.12 +4.35%
12/2010 0.16 0.21 +34.04%
09/2010 0.13 0.13 +2.63%
06/2010 0.11 0.12 +9.09%
03/2010 0.11 0.10 -9.09%
12/2009 0.14 0.12 -11.11%

Financial Strength

as of 1:10 ET PM 11/26/2021
Pre-Tax Margin -41.78
Net Margin 0.68
Operating Margin -38.53
Return On Equity -49.31
Return On Assets -18.46
Inventory Turnover (TTM) 2.71
Sales Growth (MRQ) -11.79

Ratios

as of 1:10 PM ET 11/26/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 3.73
Price/Cash Flow (TTM) 87.10
Book Value (MRQ) 0.14
Quick Ratio (MRQ) 0.10
Current Ratio (MRQ) 0.40
Total Debt/Equity (MRQ) 1.10

Short Interest

as of 12:07 PM ET 11/29/2021
% Short - 2.88%
% Remaining Float - 97.12%
Current Last Month
Short Interest Date 11/15/2021 10/29/2021
Short Interest Shares 587,308 1,068,055
Short Interest Ratio 1.4 0.2
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 1:10 ET PM 11/26/2021
Current Qtr
(12/1969)
Next Qtr
(12/1969)
Consensus Estimate n/a n/a
# of Estimates n/a n/a
High Estimate n/a n/a
Low Estimate n/a n/a
Year Ago EPS n/a n/a
Year Over Year Growth Estimate n/a n/a
Current Yr
(12/1969)
Next Yr
(12/1969)
Consensus Estimate n/a n/a
# of Estimates n/a n/a
High Estimate n/a n/a
Low Estimate n/a n/a
Year Ago EPS n/a n/a
Year Over Year Growth Estimate n/a n/a
Current Qtr
(12/1969)
Next Qtr
(12/1969)
Current Year
(12/1969)
Next Year
(12/1969)
Consensus Estimate n/a n/a n/a n/a
# of Estimates n/a n/a n/a n/a
High Estimate n/a n/a n/a n/a
Low Estimate n/a n/a n/a n/a
Year Ago EPS n/a n/a n/a n/a
Year Over Year Growth Estimate n/a n/a n/a n/a

Insider Information Summary

as of 10/31/2021
% Insiders - 53.06%
% Remaining Total Shares - 46.94%
Current 1 Month
Net Insider Transaction 1.76 M 1.76 M
Shares Bought 1.76 M 1.76 M
Shares Sold 0.00 0.00

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Money Challenges thumb

Nearly Two-Thirds of Americans Worried About Their Jobs: Bankrate

A Bankrate survey finds 3 in 5 Americans are concerned about the jobs and income sources.

Amazon, Best Buy, Walmart Are Retail Winners Over Black Friday Weekend -- Moody's Analyst

Black Friday Shoppers Boost Retailers' November Foot Traffic Numbers

November foot traffic rose nearly 260% last Friday, according to data from more than 100 top-tier indoor malls and 100 outdoor shopping centers across the country.

Zscaler Lead

5 Top Stock Gainers for Monday: Zscaler, Krystal Biotech, Adagio

Zscaler, Krystal Biotech, Adagio Therapeutics, Moderna and Royal Caribbean are five top stock gainers for Monday.

Bill Ackman

Ackman: Omicron May Be Bullish for Stocks; El-Erian Less Sanguine

'While it is too early to have definitive data, early reported data suggest omicron virus causes mild to moderate symptoms,' Bill Ackman says.

Walmart Store Accountants

BofA: Walmart, Target 'Especially Well Positioned' for Holidays

The strength for Walmart and Target stems from 'their strong omni-channel execution ... and dominant scales,' BofA said.

Twitter Lead

Buy or Sell Twitter as Dorsey Steps Down as CEO?

Twitter shares spike higher, then collapse lower on Monday on news that CEO Jack Dorsey is stepping down. Here's the trade now.

Joe Biden Lead

Biden and Walmart, CVS CEOs to Meet on Supply Chain, Omicron Variant

A Monday call between Biden and top retail executives was to address bottlenecks created by supply shortages and the Omicron variant.

AMC Entertainment Lead

AMC, Sony Offer NFTs to Advance 'Spider-Man: No Way Home' Ticket Buyers

AMC's NFT offer for 'Spider-Man: No Way Home' causes online ticket traffic to soar to its highest level.

Covid-19 Vaccine Lead

'Vaccine' Chosen as Word of The Year

The 202I prize for Merriam-Webster’s Word of the Year went to an obvious choice: vaccine.

Stronger Yen Sends Nissan's Profits South

Nissan to Invest Over $17 Billion in EVs Over Next 5 Years

Nissan hopes to roll out 23 new electric vehicle models by 2030.